← Back to Search

Behavioural Intervention

Virtual Reality Obstacle Detection for Visual Field Loss

N/A
Recruiting
Led By Jae-Hyun Jung, PhD
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to independently move short distances
Visual field loss, either peripheral field loss (<30 degrees diameter) or hemianopic field loss (blind in half of visual field)
Must not have
Any self-reported history of seizures (any type) in the last 6 months
Patients with any self-reported physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of four months
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a VR headset to help people with visual field loss practice detecting and avoiding virtual pedestrians. The headset shows 3D images of people walking towards the user while they walk in a real-world setting. This helps improve their ability to avoid collisions in a safe environment.

Who is the study for?
This trial is for people with visual field loss, such as hemianopia or tunnel vision. Participants must have binocular vision within normal limits, at least partial peripheral vision, and a visual acuity of no worse than 20/100 in the weaker eye. They should be over 14 years old, healthy enough for sessions up to 3 hours, understand English, consent voluntarily, and move independently.
What is being tested?
The study is testing a new virtual reality (VR) system designed to help individuals with visual field loss detect obstacles while walking. It involves wearing a VR headset that simulates real-world environments and oncoming pedestrians in three dimensions.
What are the potential side effects?
While not explicitly stated, potential side effects may include discomfort from wearing the VR headset, motion sickness due to virtual reality exposure, eye strain from prolonged use of the device or temporary disorientation after using the VR system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk by myself for short distances.
Select...
I have lost vision in either half or the outer parts of my field of vision.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a seizure in the past 6 months.
Select...
I do not have any physical or mental disabilities that would affect my participation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of four months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of four months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response time
Secondary study objectives
Error rate
Head movement range
Pedestrian detection rate
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Field expansion viewExperimental Treatment1 Intervention
Various configurations of field expansion views will be additionally displayed on HMD

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Homonymous Hemianopia include visual field expansion techniques, such as the use of prisms and virtual reality (VR) head-mounted displays. Prisms work by shifting images from the non-seeing side to the seeing side, thereby expanding the visual field. VR head-mounted displays create a simulated 3D environment that helps patients practice and improve their visual-motor coordination and hazard detection in a controlled setting. These mechanisms are crucial for Homonymous Hemianopia patients as they enhance their ability to navigate their environment safely and independently, improving their overall quality of life.
Effect of movement and vision on visual-motor adjustment to optical rearrangement.Wayfinding and Glaucoma: A Virtual Reality Experiment.Disparity vergence responses before versus after repetitive vergence therapy in binocularly normal controls.

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor
108 Previous Clinical Trials
13,019 Total Patients Enrolled
National Eye Institute (NEI)NIH
554 Previous Clinical Trials
1,407,324 Total Patients Enrolled
1 Trials studying Quadrantanopia
280 Patients Enrolled for Quadrantanopia
Jae-Hyun Jung, PhDPrincipal InvestigatorAssistant Scientist

Media Library

Field expansion view (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05141604 — N/A
Quadrantanopia Research Study Groups: Field expansion view
Quadrantanopia Clinical Trial 2023: Field expansion view Highlights & Side Effects. Trial Name: NCT05141604 — N/A
Field expansion view (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05141604 — N/A
Quadrantanopia Patient Testimony for trial: Trial Name: NCT05141604 — N/A
~0 spots leftby Nov 2024